Ken Griffin Humacyte, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Humacyte, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 646,500 shares of HUMA stock, worth $911,565. This represents 0.0% of its overall portfolio holdings.

Number of Shares

646,500

Previous 625,700 3.32%

Holding current value

$911,565

Previous $1.07 Million 26.38%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.15 - $2.77 $2.63 Million - $6.34 Million	-2,287,143 Reduced 78.54%	624,758 $1.31 Million
Q1 2025 May 15, 2025	BUY	$1.71 - $5.18 $4.69 Million - $14.2 Million	2,740,439 Added 1598.28%	2,911,901 $4.98 Million
Q4 2024 Feb 14, 2025	BUY	$3.46 - $5.81 $63,380 - $106,427	18,318 Added 11.96%	171,462 $865,000
Q3 2024 Nov 14, 2024	BUY	$5.11 - $9.46 $558,226 - $1.03 Million	109,242 Added 248.83%	153,144 $833,000
Q2 2024 Aug 14, 2024	SELL	$2.87 - $9.1 $603,701 - $1.91 Million	-210,349 Reduced 82.73%	43,902 $210,000
Q1 2024 May 15, 2024	BUY	$2.57 - $4.84 $177,640 - $334,545	69,121 Added 37.34%	254,251 $790,000
Q4 2023 Feb 14, 2024	SELL	$1.99 - $3.12 $185,979 - $291,585	-93,457 Reduced 33.55%	185,130 $525,000
Q3 2023 Nov 14, 2023	BUY	$2.75 - $4.48 $658,619 - $1.07 Million	239,498 Added 612.7%	278,587 $816,000
Q2 2023 Aug 14, 2023	BUY	$2.86 - $4.97 $111,794 - $194,272	39,089 New	39,089 $111,000
Q4 2022 Feb 14, 2023	SELL	$2.02 - $3.62 $340,305 - $609,854	-168,468 Reduced 99.7%	510 $1,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $5.14 $37,338 - $157,309	-30,605 Reduced 15.33%	168,978 $551,000

Others Institutions Holding HUMA

# of Institutions

171

Shares Held

54.5M

Call Options Held

1.1M

Put Options Held

808K

View Full List

About Humacyte, Inc.

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $145M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

More about HUMA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account